Sun Pharma targets its biggest overseas deal as Dilip Shanghvi doubles down on buyouts

Published on 27 April 2026

A Kolkata trader is now chasing a 12.5 billion prize

Sun Pharma, under Dilip Shanghvi, is preparing its biggest overseas acquisition: a $12.5 billion deal for Organon & Co. The move builds on Shanghvi’s buyout playbook—snapping up firms with strategic value and turnaround potential to drive global expansion. His prior deals, including Ranbaxy and Taro, show how targeted acquisitions can reshape growth across markets.

Sun Pharma plans a $12.5 billion acquisition of Organon & Co.
The deal is positioned as its largest overseas buy to date
Shanghvi’s strategy favors strategic advantage and turnaround potential
Past acquisitions like Ranbaxy and Taro helped expand globally

#sun pharma #global expansion #mergers and acquisitions #pharmaceuticals #dilip shanghvi

Read the full story at The Economic Times

This summarization was done by Beige for a story published on The Economic Times

Sun Pharma targets its biggest overseas deal as Dilip Shanghvi doubles down on buyouts

The full experience is on mobile.